Oligosaccharides from *Morinda officinalis* Slow the Progress of Aging Mice by Regulating the Key Microbiota-Metabolite Pairs

Yang Xin, Chen Diling, Chen Tianlu, Zhao Jun, Tang Xiaocui, Guo Yinrui, Shuai Ou, Deng Tianming, and Hu Guoyan

1Department of Pharmacy, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China
2State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Guangdong Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou 510070, China
3Shanghai Key Laboratory of Diabetes Mellitus and Center for Translational Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China
4Department of Obstetrics and Gynecology, Guangdong Women and Children Hospital, Guangzhou 510010, China
5Department of Geriatrics, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China
6Department of Clinical Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China

Correspondence should be addressed to Yang Xin; chemist_yx@163.com, Chen Diling; diling1983@163.com, and Deng Tianming; dtm211619@163.com

Received 1 August 2019; Revised 26 October 2019; Accepted 27 November 2019

Academic Editor: Tadaaki Satou

The gut microbiota is considered an important factor in the progression of Alzheimer’s disease (AD). Active research on the association between the metabolome and the gut microbiome is ongoing and can provide a large amount of beneficial information about the interactions between the microbiome and the metabolome. Previous studies have shown that the oligosaccharides from *Morinda officinalis* (OMO) can delay the progress of AD in model animals by regulating the diversity of the gut microbiome and metabolic components, and the correlation between the gut microbiome and metabolic components still needs to be further verified. This study applied a new two-level strategy to investigate and ensure the accuracy and consistency of the results. This strategy can be used to determine the association between the gut microbiome and serum metabolome in APP/PS1 transgenic mice and C57BL/6J male mice. The "4C0d-2 spp.-Cholesterol," "CW040 spp.-L-valine," "CW040 spp.-L-acetylcarnitine," "RF39 spp.-L-valine," "TM7-3 spp.-L-valine," and "TM7-3 spp.-L-acetylcarnitine" associations among specific "microbiota-metabolite" pairs were further identified based on univariate and multivariate correlation analyses and functional analyses. The key relevant pairs were verified by an independent oligosaccharide intervention study, and the gut microbiome and serum metabolome of the OMO intervention group were similar to those of the normal group. The results indicate that OMO can significantly suppress Alzheimer’s disease by regulating the key microbiota-metabolite pairs. Therefore, this two-level strategy is effective in identifying the principal correlations in large datasets obtained from combinations of multiomic studies and further enhancing our understanding of the correlation between the brain and gut in patients with AD.

1. Introduction

Alzheimer’s disease (AD) is a neurodegenerative disease that will affect nearly 82 million people by 2030 and 152 million people by 2050 [1], according to the 2018 World AD Congress Report. China has become the country with the largest number of AD patients in the world. At present, the incidence of AD has reached more than 8 million [2], and the incidence of AD in elderly individuals over 65 years old is 4%–6% [3], which is increasing. The cost of AD treatment would be a very large financial burden, and the public’s awareness of AD is severely inadequate [4]. The majority of patients with AD are not effectively diagnosed or treated. Therefore, the identification of markers and signaling
pathways leading to AD is essential for understanding the pathogenesis of this disease and its effective treatment.

According to recent research, multiple pathological characteristics of AD are related to gut microbial infections [5–7]. The microbiome-gut-brain axis connects nerve, hormone, and immune signals between the gut and the brain, which has profound effects on the growth and health of mammals [8]. The gut microbiota is considered an important factor for determining the progression of AD [9–11]. However, the mechanism of this relationship remains unclear. Thus, in-depth studies are required to verify the existing routes of bidirectional communication [12] to elucidate the relevant molecular mechanisms.

In the early stage, we proposed a new treatment strategy to reverse the microbiological maladjustment related to the pathological state by improving the gut microbiome of animals with AD [13]. Oligosaccharides isolated from *Morinda officinalis* (OMO) could improve the memory ability of rats with beta-amyloid-induced dementia in the water maze test [14, 15]. The SOD, CAT, and GSH-Px activities were high, and the MDA content was lowered in the brain tissue of rats with dementia, as determined by kit-based detection. In addition, the acetylcholinesterase levels decreased, the acetylcholine levels and brain energy metabolism levels increased, and Na⁺/K⁺-ATPase activity increased, indicating that OMO can significantly improve dementia symptoms in animal models of AD [16, 17]. Bajijiasu, one of the main components of OMO, is a neuroprotective agent that plays a neurotoxic protective role in AD [17–19]. This OMO component may act through antioxidant, anti-inflammatory, and neurotransmitter mechanisms to improve AD symptoms.

Furthermore, OMO can improve the function of the gut microbiota to inhibit the progression of AD [13, 20, 21]. We studied the changes in the gut microbiome and serum metabolite levels in animal models of AD [13]. Based on previous studies, it was found through bioinformatics-based mining that OMO can delay the progress of AD by regulating the key “microbiome-metabolite” pair, and preliminary data on microbiome-metabolite interactions were established. This study expands our understanding of the microbiome-gut-brain axis, as the metabolome and particularly some of the newly discovered serum metabolites may serve as the endpoints of new pathways connecting the gut to the brain.

In this study, the APPSwe/PS1dE9 (APP/PS1) transgenic mouse model [22] was used to detect changes in the gut microbiota-metabolite interactions in AD, laying a foundation for the early prevention and treatment of AD. The 16S rRNA gene in each sample from each microorganism was enriched through reversible solid-phase implantation, quantified by electrophoresis using an Agilent 2100 Bioanalyzer (Agilent, USA), and sequenced with an Illumina MiSeq sequencing system [23]. Meanwhile, we used LC-MS/MS to quantify the metabolites across groups and performed a targeted in-depth comparison of the blood metabolites from the APP/PS1 mice and C57 mice at 2 months of age. Considering the size of the dataset, the hierarchical structure of the metabolome, and the complex taxonomy of the microbiome, the metabolites and bacteria differed greatly at different levels. Thus, the use of multilevel strategies and multiple methods will simplify the complex data and ensure the accuracy and consistency of the results.

The purpose of this study is to establish a research strategy for determining the association between the microbiome and metabolome and to provide additional information on gut and brain interactions through techniques designed to analyze and mine data to identify potential therapeutic markers and to solve the complex problems associated with the pathological and pharmacological studies of AD. At the same time, this study provides new insights into the pathogenesis of AD from the perspective of microbe-metabolite correlations and may find that supplemental dietary metabolites delay AD or alleviate the pain caused by some diseases.

Thus, two levels of strategies, including microbial diversity analyses and metabolomics, were used to determine the underlying targets and mechanisms. In addition, the findings may lay the groundwork for the development of OMO as anti-AD drugs and health foods.

2. Materials and Methods

2.1. Preparation of the Animal Model. Thirty male APP/PS1 transgenic mice (2 months old) and 10 C57BL/6J male mice (2 months old) of the same age and genetic background were purchased from Beijing HFK Bioscience Co., Ltd. (certificate no. SCXK (Jing) 2014–0004); the mice had a mean body weight of 20 ± 5 g. The mice were housed in plastic cages in a temperature-controlled (25°C) colony room on a 12/12 h light/dark cycle. All animal experiments began at least 4 weeks after the animals arrived. The experimental mice were divided into three groups: the model group (APP/PS1 transgenic mice orally administered distilled water, *n* = 10), the normal group (C57BL/6J mice orally administered distilled water, *n* = 10), and the OMO administration group (APP/PS1 transgenic orally administered 100 mg/(kg·d) OMO, *n* = 10). Food and water were provided ad libitum. All experimental procedures were approved by the Center of Laboratory Animals of the Guangdong Institute of Microbiology.

2.2. Measurement of AD Parameters. The appearance and behavior of the animals were observed and recorded daily. The animal weights were measured every three days during the study. Following OMO treatment for 6 months, all animals were sacrificed; their eyeballs were removed, and their blood and brain tissue were collected. Routine serum parameters and cytokine levels [24] were measured, and the brains of the mice were dissected. Five brains from each group were fixed with a 4% paraformaldehyde solution, embedded in paraffin, and sectioned. Sections were stained with hematoxylin-eosin (H&E) or subjected to immunohistochemical staining and observed under a light microscope [17, 25]. All animal handling procedures and experiments were performed strictly in accordance with the
recommendations of the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health. The experimental protocol was approved by the Laboratory Animal Center and the Ethical Committee of the Guangdong Institute of Microbiology, Guangzhou, China. Each procedure described in our study was approved by the Laboratory Animal Center of the Guangdong Institute of Microbiology. This study utilized as few mice as possible.

2.3. 16S rRNA Analysis. Fecal specimens were acquired from the home cages of the mice and stored at −80°C until the 16S rRNA analysis. The QIAamp DNA Stool Mini Kit was used for extraction, and the extracted DNA was detected. The quality of the extracted DNA was determined by 0.8% agarose gel electrophoresis, and the DNA was quantified by a UV spectrophotometer. The 16S rRNA genes of the microbes were amplified with the following primers: forward 5′-ACTCCTACGGGAGGCAGCA-3′ and reverse 5′-GGACTACHVGGGTWTCTAAT-3′. Every amplified product was concentrated by SPRI, and an Agilent 2100 Bioanalyzer was used to quantify the samples subjected to electrophoresis. Every specimen was diluted to 1 × 10^9 molecules/μL in TE buffer and pooled into groups prior to the determination of DNA concentrations using a NanoDrop spectrophotometer. An Illumina MiSeq sequencing system was utilized to sequence 20 μL of the pooled admixture, and the subsequent reads were analyzed.

2.4. Metabolomics Analysis. Serum samples were treated as described in a previous study [13]. The processed samples were loaded into a tube lining a sample vial and analyzed using LC-MS (Thermo Fisher Scientific, USA). The chromatographic column was an Acquity BEH C18 column (100 mm × 2.1 mm internal diameter, 1.7 μm; Waters, Milford, USA). Mobile phase A was water (0.1% (v/v) formic acid), mobile phase B was acetonitrile (0.1% (v/v) formic acid), the flow rate was 0.40 mL/min, the injection volume was 3 μL, and the column temperature was 45.0°C. Mass spectrometry data were acquired from 50 to 1,000 m/z with a resolution of 30,000. Metabolites were measured by a UPLC/LTQ Orbitrap mass spectrometer equipped with an electrospray interface (Thermo Fisher Scientific, USA).

2.5. Association Analysis. Alterations in the gut microbiome and serum metabolome of the normal and model groups were evaluated. The proportions of different metabolites were calculated by summing the levels of all metabolites (normalized by row, within each variable) of the corresponding types. The phyla were determined by summing all OTUs of the corresponding phyla. Then, a two-level strategy was adopted to determine the key association pairs. For the high-level association analysis, considering the size and complexity of the omics data, correlations between metabolite types and bacterial phyla were examined. The key “bacterial phylum-metabolite type” pairs were selected based on the results of (1) the regularized canonical correlation analysis (rCCA) [26] and Spearman correlation analysis on the abundance datasets [27], (2) relative abundance analysis of the phyla derived from the bacterial data, and (3) the Spearman correlation coefficient for each metabolite type and each bacterial phylum. Correlation networks were constructed based on the results from the correlation analyses, and all specific “bacterium-metabolite” association pairs were listed. Significant key pairs were selected for further analyses. Finally, the key pairs were validated in an OMO intervention study.

2.6. Statistical Analysis. All data presented in the figures are reported as the means ± standard deviations of at least three independent experiments. Significant differences between treatments were analyzed by the Kruskal–Wallis test/one-way analysis of variance (ANOVA) and set to p < 0.05 using the statistical packages in MATLAB (R2014a, MathWorks, USA), R (3.5.1), GraphPad Prism 7 (USA), and Cytoscape (3.6.1).

3. Results

3.1. Pathological Changes in the Normal and Model Groups. Nissl staining revealed more neurons (blue points) in the normal group than in the model group (Figure 1(a)). More hippocampal neurons were observed in the normal group than in the model group. H&E staining did not reveal obvious neuronal abnormalities in the hippocampus of the normal group (Figure 1(b)). The pyramidal cells in the CA1 region were arranged neatly and tightly, and no cells were lost. However, obvious histopathological damage to the hippocampus was observed in the model group. The layered pyramidal neuron structure was disintegrated, and neurons were lost in the CA1 region. Neurons with pyknotic nuclei and with shrunken or irregular shapes were also observed. Immunofluorescence staining showed an intense red color (p-tau and Aβ1-42) throughout the hippocampal region of the APP/PS1 double transgenic mice, while in the normal group, the RLU was obviously reduced. In CA1, the expression of p-tau and Aβ1-42 (red fluorescence) was barely detectable (Figures 1(c) and 1(d)).

3.2. Alterations in the Gut Microbiome and Metabolome. In this study, 11 bacterial phyla, 20 bacterial orders, 20 bacterial genera, 20 bacterial families, 20 bacterial classes (Figures 1(e) and 1(i)), and 102 different metabolites (11 metabolite types) were analyzed (Figures 2(a) and 2(b)). Firmicutes and Bacteroidetes were the predominant bacterial phyla found in the gut, while fatty acids and phosphatidylcholine (PC) were the predominant types of metabolites detected and accounted for 48.04% of all metabolites. The Shannon indexes (Figure 2(c)) revealed a higher gut microbiome diversity in the APP/PS1 transgenic mice than in the C57 mice. Alterations in the gut microbiome and metabolome were further evaluated by determining the relative abundances of bacterial phyla and metabolite types in the normal and model groups. As expected, both high and low abundance variables changed substantially. The Kruskal–Wallis test/one-way ANOVA...
Figure 1: Continued.
revealed significant changes in eight metabolites (Figures 2(a) and 2(b)), namely, fatty acids, cholic acid, phosphatidylinositol (PI), phosphatidylglycerol (PG), phosphatidylethanolamine (PE), PC, amino acids, and lysophosphatidylcholine (LPC), and five bacterial phyla (Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, and Cyanobacteria) (Figure 1(e)) between the two groups.

3.3. Correlation Analysis of the "Microbiota Phylum-Metabolite Type" Pairs. The loading value (descending order) of each bacterial gate and metabolite type was calculated by rCCA, as shown in Figures 3(a) and 3(b). The loading values of eight bacterial phyla (Cyanobacteria, Proteobacteria, Firmicutes, Tenericutes, Bacteroidetes, Deferrribacteres, Verrucomicrobia, and TM7) and ten metabolite types (PE, cholic acid, lysophosphatidylethanolamine, lipids, PC, amino acids, phosphatidylglycerol, monoaclylglycerol, fatty acids, and LPC) were higher than the other parameters, indicating their greater contributions to the overall correlation between healthy and AD model mice.

Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) was used to predict the Kyoto Encyclopedia of Genes and Genomes (KEGG) functions based on the predicted abundance distribution of each functional group, and the findings are shown in a violin plot. The 12 significantly differential metabolic functions that were identified are shown in Figure 3(c). The abscissa is the second functional group from KEGG, and the ordinate is the relative abundance of each functional group in each sample. Metabolic functions related to lipids, cofactors and vitamins, energy, amino acids, carbohydrates, and nucleotides were significantly altered between groups. The predicted metabolic functions are of great significance for the study of AD. As shown in
Figure 2: Continued.
Figure 2: The serum metabolome composition and alterations across the AD study. (a) Heatmap of differential metabolic products between the normal group and model group. (b) Serum metabolome composition. (c) Shannon indexes of gut microbiome diversity. Normal represents the C57 group, and model denotes the APP/PS1 transgenic group; the management cycle was 6 months ($n = 8$). Values are presented as the means ± SDs of two independent experiments.

Figure 3: Continued.
Figures 4(a) and 4(b), the differentiation of the predicted metabolic functions (Figure 4(a)) and metabolite types (Figure 4(b)) varied between the two groups. The correlation coefficient for amino acid metabolic function and amino acid was $-0.58$ ($p < 0.05$, Figure 4), and these parameters were negatively correlated. This suggests that the amino acids in serum may be related to the metabolism and consumption of amino acids in other tissues. Compared with the control group, the amino acid, PE, LPE, and PC metabolites were significantly different in the model group ($p < 0.05$, Figure 4(b)).

The classic Spearman correlation analysis was performed on abundance datasets to estimate the correlations between each bacterial phylum and every metabolite type (Figure 5). The top three metabolite types that correlated with the greatest number of bacterial phyla were amino acids, lysophosphatidylethanolamine, and PC, and the top three phyla that correlated with the greatest number of metabolite types were TM7, Tenericutes, and Cyanobacteria.

Based on these results, the variable abundance and biological significance, “lips-TM7,” “amino acids-Tenericutes,” “lysophosphatidylethanolamine-Cyanobacteria,” and “PC-Cyanobacteria” were selected as key correlated pairs (Figure 5(i)). Figures 5(a)–5(h) show scatter plots of these pairs, and their correlation coefficients were 0.53, 0.58, 0.64, 0.59, 0.54, 0.52, 0.54, and $-0.51$ ($p < 0.05$).

### 3.4. Correlation Analysis of the “Microbiota-Metabolite” Pairs.

In the normal group, 70 species and 267 genera were annotated in 4421 OTUs, and in the model group, 52 species and 289 genera were annotated in 4472 OTUs. A pairwise Spearman correlation analysis was conducted on the 111 bacteria (11 phyla, 20 orders, 20 genera, 20 families, 20 classes, and 20 species) and 102 metabolites. The results for 336 of the over 3300 pairs (9.82%) were significant after the FDR correction. Among these pairs, 187 (55.7%) were positively correlated, and 149 (44.3%) were negatively correlated. Figure 6 shows the two correlation networks of bacterial genera/species (dot) and metabolites (triangle) with positive contributions (consistent correlation directions) to the five high-level key pairs. Four PCs, 6 PEs, 1 lipid, 4 fatty acids, 1 diacylglycerol (DG), 1 amino acid, 2 genera/species in TM7, 4 genera/species in Cyanobacteria,
Figure 4: Continued.

- Carbohydrate metabolism
- Amino acid metabolism
- Glycan biosynthesis and metabolism
- Energy metabolism
- Metabolism of cofactors and vitamins
- Enzyme families
- Nucleotide metabolism
- Lipid metabolism
- Metabolism of terpenoids and polyketides
2 genera/species in Tenericutes, and 1 genus in Deferribacteres were involved. The red and blue lines indicate positive and negative correlations, respectively. The size of each node is proportional to the number of lines connected to it, and the node shape indicates different bacterial classes and metabolite subtypes. Green represents bacteria, and red represents metabolites. The most extensively connected nodes are the key bacteria or metabolites. Four groups of correlation pairs were prominent, including (1) *4C0d*-2 spp. in the phylum Cyanobacteria with 4 PEs, 4 PCs, and 1 lipid; (2) *CW040* spp. in the phylum TM7 with 1 citric acid, 2 amino acids, 1 DG, and 1 PE and TM7-3 spp. in the phylum TM7 with 1 DG and 1 amino acid; (3) *Deferribacteres* spp. in the phylum Deferribacteres with 4 fatty

Figure 4: Differences in the predicted metabolic functions and levels of various metabolites in the two groups. Values are presented as the means ± SDs from six independent experiments. *p < 0.05 compared with the normal group; **p < 0.01 compared with the model group.
Figure 5: Results of the correlation analysis of the “microbial phylum–metabolite type” pairs in the AD study. (a–h) Scatter plots of the eight key high-level pairs. (i) Spearman correlation heatmap for each microbial phylum and each metabolite type (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$).

Figure 6: Continued.
acids and 1 amino acid and the phylum Deferribacteres with 5 fatty acids and 1 amino acid; and (4) RF39 spp. in the phylum Tenericutes with 1 amino acid and 1 citric acid. In Figure 6, two hub nodes (L-valine and L-acetylcarnitine) are highlighted, as they are all correlated with 6 bacteria, with comparable strengths.

First, both Cyanobacteria (4C0d-2 spp.) and lipids are associated with brain development and disease. Cyanobacteria produce different complex lipid secondary metabolites [28] and possess strong biological properties and application value, such as antibacterial, antifungal, anticancer, antituberculosis, immunosuppressive, and anti-
Evidence-Based Complementary and Alternative Medicine 13

inflammatory properties. Over the past decade, AD has been shown to be closely related to changes in lipid levels or lipid metabolism. Thus, Cyanobacteria metabolize lipid products that may be associated with the progression of AD [29].

Second, in this report, TM7 was negatively correlated with lipids, and Cyanobacteria (4C0d-2 spp.) was negatively correlated with PC. Among these metabolites, cholesterol [30], PC (22:0(14Z, 17Z)/20:0(15Z)), and LPC, PC, and PC, which are important for synaptic activity and protein synthesis. Another example of a combination with strategies, and “Tenericutes-amino acid,” “Tenericutes-PC,” “Cyanobacteria-LPE,” “Cyanobacteria-PC,” and “TM7-cholesterol” were identified as probable key endpoints in the two studies.

The relative abundance of CW040 [42] and TM7-3 (TM7) was increased in the model group, and the abundance of Deferribacterales (Deferribacteres) was decreased (Figures 1(e), 1(f), and 1(i)). The level of the metabolite L-acylcarnitine [43] was increased in the OMO group, and the levels of cholesterol [44] and L-valine were decreased (Figure 2(a) and Figures 7(a)–7(l)). The pathological changes observed were alleviated in the OMO intervention experiment [13].

Collectively, the association directions of the key correlation pairs were largely consistent in the two studies. These microorganisms and metabolites may be potential targets for the treatment of AD. However, the intestinal microorganisms and metabolites in animal and human samples also differ, and these “microbiome-metabolite” pairs are key to specific change rules that need to be further studied. Thus, we should exercise caution when applying the findings from animal experiments to humans.

3.6. Possible Routes Connecting the Gut and Metabolites. We used both microbial and metabolomic analytical strategies, and “Tenericutes-amino acid,” “Tenericutes-PC,” “Cyanobacteria-LPE,” “Cyanobacteria-PC,” and “TM7-cholesterol” were identified as probable key endpoints in the pathway that connects the brain to the gut.

The two-level analysis of microorganisms and metabolites was an effective method to simplify complex data and effectively identify the correlations. However, this strategy may ignore less statistically significant but more biologically relevant factors, such as the types of microphytes and metabolites that are not selected as key pairs but play an important role in the gut-brain interaction.

As shown in Figure 5(i), LPE was strongly and positively correlated with not only Tenericutes but also Cyanobacteria and Firmicutes. In addition to its correlation with LPE, Tenericutes was also closely correlated with amino acids, LPC, and PC, which are important for synaptic activity and protein synthesis. Another example of a combination with low statistical significance but high biological significance was the “microbiota-metabolite” pairs; the metabolites were not correlated with five key high-level microbial phyla but may also improve our understanding of the microbial-gut-brain axis. These pairs included species in the orders Clostridiales/Lactobacillales/Erysipelotrichales/Bacillales/Turicibacterales and lipids; species in the orders Bacteroidales/Flavobacteriales and PC; species in the orders Enterobacteriales/Desulfovibrionales/Campylobacterales/Burkholderiales/Pseudomonadaceae/Hydrogenophilales/Chromatiales/HOC36/Desulfaccales and fatty acids; Verrucomicrobiales and deconiac acid; and species in the orders Coriobacterales/Bifidobacteriales/Actinomycetales and deconiac acid. Although these microbes and metabolites...
exert important effects on brain and intestinal health [12, 45], the overall performance of each metabolite type or phylum was not statistically significant. Therefore, the biological significance of a low-level correlation without a hierarchical relationship between the low-level correlation and high-level key correlation should be carefully evaluated when applying the two-level strategy to analyze the microbiota and metabolites.

**4. Discussion and Conclusion**

As China becomes an aging society, the increasing incidence of AD will be a heavy burden for society and for medical care, so new treatments and potential drugs are urgently needed. The evidence shows that the pathological features of AD are related to microbial infection, so the gut microbiota is considered an important factor determining the progression of AD. Previous studies have shown that OMO can improve the symptoms of animal models of AD, which is related to regulation of the diversity of the gut microbiota and metabolic components. The two-level strategy confirmed the relevance between AD disease and key microbiota-metabolic components, and the OMO intervention studies further validated their relationship.

Lipids are a group of metabolites with multiple biological functions that are closely related to various metabolites [46]. Based on accumulating evidence, the gut microbiota, as an environmental factor, modulates the processing, absorption, metabolism, storage, clearance, and other systemic functions of host lipids in the elderly [47–49]. Fatty acids are a group of carboxylic acids with different numbers of aliphatic chains that are either saturated or unsaturated. A large number of studies have revealed the remarkable effects of free fatty acid metabolism on brain circulation, structure, and function at different ages [50]. According to some studies [51, 52], old mice display significantly increased levels of both amino acids and fatty acids, which are closely associated with AD biomarkers, compared to young mice. In the intestinal microbiome analyses, the Firmicutes/Bacteroidetes ratio and alpha diversity were increased in older mice.

The gut microbiota synthesizes a variety of nutrients and essential amino acids, representing a potential mechanism for regulation of amino acid homeostasis [53]. In recent years, close relations between the human gut microbiome, the physiological aspects of its metabolites and hosts, and the important pathological and physiological dimensions of diseases have been identified [53]. Amino acids are involved in many cellular metabolic and signaling pathways, and the effects of changes in amino acid metabolism are far-reaching in patients with AD [54].

PC and PE are the most abundant phospholipids in mammalian cell membranes [55]. Decreased levels of PC, which lead to decreased numbers of synapses in the brain, are a characteristic of memory disorders in patients with early AD [31]. PE [56] has a variety of cellular functions, including serving as a precursor of PC and as an important posttranslational substrate, affecting membrane topologies and facilitating cell and organelle membrane fusion, oxidative phosphorylation, mitochondrial biogenesis, and autophagy. The importance of PE metabolism in mammalian health has recently been revealed based on its associations with AD, Parkinson’s disease (PD), nonalcoholic liver disease, and some pathogenic microorganisms [57]. Dietary nutrients containing PC and PE may be involved in the development of AD. The nutrients, the gut microbiota, and host participation in these metabolic pathways may be new targets for the prevention and treatment of AD.

Firmicutes and Bacteroidetes are known to be the dominant phyla in the gut and are involved in many brain functions [58]. They are also reported to be the phyla that display the greatest variation across their life cycles, independent of gender, age, and nationality [59]. However, clear relationships between these bacteria and the progression of AD have not been determined. Tenericutes [60] are unique and rare bacteria with no cell walls, and they survive as typical parasites or eukaryotic host symbionts. Environmental 16S rDNA investigations have identified several branches of Tenericutes in different environments, suggesting that these Tenericutes may represent free-living microorganisms that are independent of the host. The diversity of the fecal microflora in patients with polycystic ovary syndrome was low, and their phylogenetic components were altered. When rare taxa were observed, the relative abundance of the bacteria from the phylum Tenericutes was significantly reduced [61] and was correlated with reproductive parameters.

Cyanobacteria are microorganisms found in marine, freshwater, and terrestrial environments worldwide. Under favorable conditions, they form a large number of populations that harm human and animal health [58]. Toxins produced by Cyanobacteria may cause some form of nerve damage, and many of their effects are consistent with neurodegeneration [62]. Recently, a neurotoxin produced by Cyanobacteria that can cause neurodegenerative disease in humans was detected in the brain and cerebrospinal fluid of a patient with AD [63].

The key roles of the microbiome-gut-brain axis in the human lifespan [64, 65] and the patterns of characteristic changes in the gut microbiota [66–69] are actively being studied; furthermore, the metabolome has been extensively studied separately in the context of AD [70–73]. The main contribution of this report is that it is a groundbreaking joint study that uses two histological platforms to study the gut microbiome and brain metabolome of AD models. However, the intestinal microorganisms and metabolites of animal and human samples also differ. The associations identified in transgenic animals must be carefully verified in humans and further evaluated under different pathological conditions. The subsequent key pairs should be validated by further sequencing. More information can be obtained from the blood and fecal metabolome and microbiome, further confirming the connection between the blood metabolome and the intestinal microbiome and thus further establishing a systematic and integral network connecting the brain and gut.

The second contribution of this report is the design of key and relevant screening strategies. Considering the size of the dataset, the complex taxonomy of the microbiome, the
hierarchical structure of the metabolome, and the diverse performance of metabolites and bacteria at different levels, as well as the unpredictable cross-correlations within the metabolome and microbiome, we conducted a two-level correlation analysis using data from the normal and AD model groups. In the first level, the univariate and multivariate correlation analyses and functional analysis were combined to select the key pairs. In the second level, we focused on pairing with a positive contribution to high-level pairing. The multilevel strategy and multiple methods simplified the complex data and ensured the accuracy and consistency of the results.

In addition to the emphasis on the correlated bacterial-metabolic pairs, other allelopathic correlations are worthy of further study. However, due to the limited size of our sample and the limitations of the APP transgenic mouse model, we may have missed some relationships observed in different types of AD.

We report a two-level association strategy for the analysis of the gut microbiome and metabolome in samples from the two groups. The high-level “bacterial phylum-metabolite type” and the lower-level “microbe-metabolite” correlation pairs were identified by an rCCA and Spearman correlation analysis. Correlation networks were constructed based on the results from the correlation analyses, and all the specific “microbiota-metabolite” association pairs were listed. Six associations of specific “microbiota-metabolite” pairs were further identified. The key relevant pairs were verified by an independent oligosaccharide intervention study, and the gut microbiome and serum metabolome of the OMO intervention group were similar to those of the normal group in the overall adjusted models.

However, current studies have shown that intestinal microorganisms and metabolites differ in both animal and human samples of AD at different stages, and it is not clear whether the key “microbe-metabolite” pairs have biological effects at other stages. We selected only one point in the present study, but the regular changes in “microbiome-metabolite” pairs at each stage will be further studied in the future.

Therefore, this study is a good start, and our findings offer new and early insights into the interactions between the blood metabolome and gut microbiome, indicating new potential pathways that connect the gut and brain and improving our understanding of the microbial-gut-brain axis. In future studies, we must further harness metagenomics to identify 1-2 bacterial strain and metabolite pairs that will be verified in animal experiments.

**Abbreviations**

| Abbreviation | Description                  |
|--------------|------------------------------|
| AD           | Alzheimer’s disease          |
| OMO          | Oligosaccharides isolated from Morinda officinalis |
| APP/PS1      | APPswe/PS1dE9                |
| rCCA         | Regularized canonical correlation analysis |
| ANOVA        | Analysis of variance         |
| PC           | Phosphatidylcholine           |
| PI           | Phosphatidylglycerol          |
| PE           | Phosphatidylethanolamine      |
| LPC          | Lysophosphatidylcholine       |
| PICRUSt      | Phylogenetic Investigation of Communities by Reconstruction of Unobserved States |
| KEGG         | Kyoto Encyclopedia of Genes and Genomes |

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Ethical Approval**

Each procedure described in our study was approved by the Laboratory Animal Center of the Guangdong Institute of Microbiology. Our research was approved by the Ethical Committee and complied with the Declaration of Helsinki.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

Yang Xin, Chen Diling, and Chen Tianlu contributed equally to this work. YX, CD, CT, ZJ, TX, GY, SO, DT, and HG conceived and designed the experiments. YX, CD, CT, and TX performed the experiments. YX, CD, CT, ZJ, and HG analyzed the data. YX and CD wrote the paper and edited the manuscript. All the authors read and approved the final manuscript.

**Acknowledgments**

The authors gratefully acknowledge the many researchers whose efforts contributed to the assembly and characterization of these datasets. The present work received financial support from the Guangdong Science and Technology Plan Projects (2016A050502032, 2016A020215022 and 201604020009), the High-Level Leading Talent Introduction Program of GDAS (2016GDASRC-0102), Guangzhou Traditional Chinese Medicine and Integrated Chinese and Western Medicine Science and Technology Project (20192A011019), and National Natural Science Foundation of China (81701086).

**References**

[1] WHO. Dementia, 2017, http://www.who.int/news-room/factsheets/detail/dementia.
[2] J. Jia, X. Zuo, X. F. Jia et al., “Diagnosis and treatment of dementia in neurology outpatient departments of general hospitals in China,” Alzheimer’s & Dementia, vol. 12, no. 4, pp. 446–453, 2016.
[3] J. Jia, F. Wang, C. Wei et al., “The prevalence of dementia in urban and rural areas of China,” Alzheimer’s and Dementia, vol. 10, no. 1, pp. 1–9, 2014.
[4] Alzheimer’s Association, “2016 Alzheimer’s disease facts and figures,” Alzheimer’s and Dementia, vol. 12, no. 4, pp. 459–509, 2016.
Evidence-Based Complementary and Alternative Medicine

[5] C. Heintz and W. Mair, "You are what you host: microbiome modulation of the aging process," Cell, vol. 156, no. 3, pp. 408–411, 2014.

[6] W. S. Huang, T. Y. Yang, W. C. Shen, C. L. Lin, M. C. Lin, and C. H. Kao, "Association between Helicobacter pylori infection and dementia," Journal of Clinical Neuroscience, vol. 21, no. 8, pp. 1355–1358, 2014.

[7] R. Mancuso, F. Baglio, M. Cabinio et al., "Titers of herpes simplex virus type 1 antibodies positively correlate with grey matter volumes in Alzheimer's disease," Journal of Alzheimer's disease, vol. 38, no. 4, pp. 741–745, 2014.

[8] J. A. Foster, M. Lyte, E. Meyer, and J. F. Cryan, "Gut microbiota and brain function: an evolving field in neuroscience," International Journal of Neuropsychopharmacology, vol. 19, no. 5, Article ID pyv114, 2016.

[9] F. Pistollato, S. Sumalla Cano, I. Elio, M. Masias Vergara, F. Giampieri, and M. Battino, "Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease," Nutrition Reviews, vol. 74, no. 10, pp. 624–634, 2016.

[10] Y. Zhao, V. Jaber, and W. J. Lukiv, "Secretory products of the human GI tract microbiome and their potential impact on Alzheimer's disease (AD): detection of lipopolysaccharide (LPS) in AD Hippocampus," Frontiers in Cellular and Infection Microbiology, vol. 7, p. 318, 2017.

[11] D. Erny and M. Prinz, "Gut microbes augment neurodegeneration," Nature, vol. 544, no. 7650, pp. 304-305, 2017.

[12] E. A. Mayer, "Gut feelings: the emerging biology of gut-brain communication," Nature Reviews Neuroscience, vol. 12, no. 8, pp. 453–466, 2011.

[13] Y. Xin, C. Diling, Y. Jian et al., "Effects of oligosaccharides from Morinda officinalis on gut microbiota and metabolome of APP/PS1 transgenic mice," Frontiers in Neurology, vol. 9, p. 412, 2018.

[14] D. L. Chen, Z. Peng, L. Li, H. M. Zhang, and S. H. Liu, "Effect of oligosaccharides from Morinda officinalis on β-amylod-induced learning and memory dysfunction in rats," Frontiers in Neurology, vol. 29, no. 2, pp. 271–276, 2013.

[15] B. X. Tan, W. Su, J. W. Chen, C. F. Chen, Y. Wang, and X. Y. Li, "Improvement effect of bajiaosu on spatial learning and memory ability of rats," Traditional Chinese Drug Research & Clinical Pharmacology, vol. 11, no. 2, pp. 95–97, 2000.

[16] D. L. Chen, P. Zhang, L. Lin, H. M. Zhang, and S. H. Liu, "Protective effect of oligosaccharides from Morinda officinalis on beta-amylod-induced dementia rats," Zhongguo Zhong Yao Za Zhi, vol. 38, no. 9, pp. 1306–1309, 2013.

[17] D. L. Chen, P. Zhang, L. Lin et al., "Protective effects of bajiaosu in a rat model of Abeta(2)(5)/(3)(3)5-induced neurotoxicity," Journal of Ethnopharmacology, vol. 154, no. 1, pp. 206–217, 2014.

[18] D.-L. Chen, P. Zhang, L. Lin et al., "Protective effect of bajiaosu against cognitive impairment induced by amyloid-β in APP/PS1 mice," Oncotarget, vol. 8, no. 54, pp. 92621–92634, 2017.

[19] H. Cai, Y. Wang, J. He et al., "Neuroprotective effects of bajiaosu against cognitive impairment induced by amyloid-β in APP/PS1 mice," Oncotarget, vol. 8, no. 54, pp. 92621–92634, 2017.

[20] N. Yang, Y. Wei, Q. Xu, and B. Tang, "Progress in epigenetic research on Alzheimer disease," Zhonghua Yi Xue Yi Chuan Xue Za Zhi, vol. 33, no. 2, pp. 252–255, 2016.

[21] D. Chen, X. Yang, J. Yang et al., "Prebiotic effect of fructooligosaccharides from Morinda officinalis on Alzheimer's disease in rodent models by targeting the microbiota-gut-brain axis," Frontiers in Aging Neuroscience, vol. 9, p. 403, 2017.

[22] T. Melnikova, A. Savonenko, Q. Wang et al., "Cyclooxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern," Neuroscience, vol. 141, no. 3, pp. 1149–1162, 2006.

[23] Z. Ling, X. Liu, X. Jia et al., "Impacts of infection with different toxigenic Clostridium difficile strains on faecal microbiota in children," Scientific Reports, vol. 4, no. 1, p. 7485, 2014.

[24] X. Wang, G. J. Li, H. X. Hu et al., "Cerebral mTOR signal and pro-inflammatory cytokines in Alzheimer's disease rats," Translational Neuroscience, vol. 7, no. 1, pp. 151–157, 2016.

[25] G.-f. Zeng, Z.-y. Zhang, L. Lu, D.-q. Xiao, S.-h. Zong, and J.-m. He, "Protective effects of ginger root extract on Alzheimer disease-induced behavioral dysfunction in rats," Rejuvenation Research, vol. 16, no. 2, pp. 124–133, 2013.

[26] I. Montoliu, O. Cominetti, C. L. Boulangé et al., "Modeling longitudinal metabolomics and microbiota interactions in C57BL/6 mice fed a high fat diet," Analytical Chemistry, vol. 88, no. 15, pp. 7617–7626, 2016.

[27] P. Schober, C. Boer, and L. A. Schwarte, "Correlation coefficients," Anesthesia & Analgesia, vol. 126, no. 5, pp. 1763–1768, 2018.

[28] S. A. A. Shah, N. Akhter, B. N. Auckloo et al., "Structural diversity, biological properties and applications of natural products from cyanobacteria. A review," Marine Drugs, vol. 15, 11 pages, 2017.

[29] M. O. W. Grimm, D. M. Michaelson, and T. Hartmann, "Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention," Journal of Lipid Research, vol. 58, no. 11, pp. 2083–2101, 2017.

[30] H. J. Lee, K. J. Korshavn, A. Koch, J. S. Derrick, and M. H. Lim, "Cholesterol and metal ions in Alzheimer's disease," Chemical Society Review, vol. 43, no. 19, pp. 6672–6682, 2014.

[31] R. J. Wurtman, "How anticholinergic drugs might promote Alzheimer's disease: more amyloid-β and less phosphatidylcholine," Journal of Alzheimer's Disease, vol. 46, no. 4, pp. 983–987, 2015.

[32] F. O. Bastian, "Combined creutzfeldt-Jakob/Alzheimer's disease cases are important in search for microbes in Alzheimer's disease," Journal of Alzheimer's Disease, vol. 56, no. 3, pp. 867–873, 2017.

[33] K. A. Scott, M. Ida, V. L. Peterson et al., "Revisiting metchinkoff: age-related alterations in microbiota-gut-brain axis in the mouse," Brain, Behavior, and Immunity, vol. 65, pp. 20–32, 2017.

[34] A. Villegas, F. Lopera, and G. P. Cardona-Gomez, "Different pattern of phospholipid profile in the temporal cortex from E280A-familiar and sporadic Alzheimer's disease cases are important in search for microbes in Alzheimer's disease," Frontiers in Aging Neuroscience, vol. 9, pp. 208–210, 2017.

[35] R. J. Wurtman, "How anticholinergic drugs might promote Alzheimer's disease: more amyloid-β and less phosphatidylcholine," Journal of Alzheimer's Disease, vol. 46, no. 4, pp. 983–987, 2015.

[36] F. O. Bastian, "Combined creutzfeldt-Jakob/Alzheimer's disease cases are important in search for microbes in Alzheimer's disease," Journal of Alzheimer's Disease, vol. 56, no. 3, pp. 867–873, 2017.

[37] K. A. Scott, M. Ida, V. L. Peterson et al., "Revisiting metchinkoff: age-related alterations in microbiota-gut-brain axis in the mouse," Brain, Behavior, and Immunity, vol. 65, pp. 20–32, 2017.

[38] G. Villamil-Ortiz, A. Barrera-Ocampo, J. D. Arias-Londono, A. Villegas, F. Lopera, and G. P. Cardona-Gomez, "Differential pattern of phospholipid profile in the temporal cortex from E280A-familiar and sporadic Alzheimer's disease brains," Journal of Alzheimer's Disease, vol. 61, no. 1, pp. 209–219, 2018.

[39] P. L. Wood, S. Tippireddy, J. Feriante, and R. L. Woltjer, "Augmented frontal cortex diaacetylcerol levels in Parkinson's disease and Lewy Body Disease," PLoS One, vol. 13, no. 3, Article ID e0191815, 2018.

[40] M. Pfueffer and A. Jaudszus, "Pentadecanoic and heptadecanoic acids: multifaceted odd-chain fatty acids," Advances in Nutrition: An International Review Journal, vol. 7, no. 4, pp. 730–734, 2016.
Evidence-Based Complementary and Alternative Medicine

[37] K. Goozee, P. Chatterjee, I. James et al., "Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease," *Scientific Reports*, vol. 7, no. 1, p. 676, 2017.

[38] K. C. Sonntag, W. I. Ryu, K. M. Amirault et al., "Late-onset Alzheimer’s disease is associated with inherent changes in bioenergetics profiles," *Scientific Reports*, vol. 7, no. 1, p. 14038, 2017.

[39] E. Kim, H. J. Ko, S. J. Jeon et al., "The memory-enhancing effect of erucic acid on scopalamine-induced cognitive impairment in mice," *Pharmacology Biochemistry and Behavior*, vol. 142, pp. 85–90, 2016.

[40] R. J. Pawlosky, M. F. Kemper, Y. Kashiwaya, M. T. King, K. Goozee, P. Chatterjee, I. James et al., "Alterations in intestinal microbiome in senescence-accelerated mouse prone 8 strain, a mouse model of Alzheimer’s disease," *Scientific Reports*, vol. 20, no. 2, pp. 195–207, 2017.

[41] A. Kitamura, T. Tsurugiawa, A. Uematsu, K. Torii, and H. Uenayama, "New therapeutic strategy for amino acid medicine: effects of dietary glutamate on gut and brain function," *Journal of Pharmacological Sciences*, vol. 118, no. 2, pp. 138–144, 2012.

[42] J. Wang, F. Ye, X. Cheng et al., "The effects of LW-AFC on intestinal microbiome in senescence-accelerated mouse prone 8 strain, a mouse model of Alzheimer’s disease," *Journal of Alzheimer’s Disease*, vol. 53, no. 3, pp. 907–919, 2016.

[43] Y. Gong, Y. Liu, L. Zhou et al., "A UHPLC-TOF/MS method based metabonomic study of total ginsenosides effects on Alzheimer disease mouse model," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 115, pp. 174–182, 2015.

[44] J. E. Simpson, P. G. Ince, T. Minett et al., "Neuronal DNA damage response-associated dysregulation of signalling pathways and cholesterol metabolism at the earliest stages of Alzheimer-type pathology," *Neuropathology and Applied Neurobiology*, vol. 42, no. 2, pp. 167–179, 2016.

[45] S. M. Collins, M. Surette, and P. Bercik, "The interplay between the intestinal microbiota and the brain," *Nature Reviews Microbiology*, vol. 10, no. 11, pp. 735–742, 2012.

[46] X. Han, "Lipidomics for studying metabolism," *Nature Reviews Endocrinology*, vol. 12, no. 11, pp. 668–679, 2016.

[47] R. L. Greer, A. Morgun, and N. Shulzenko, "Bridging immunity and lipid metabolism by gut microbiota," *Journal of Allergy and Clinical Immunology*, vol. 132, no. 2, pp. 253–262, 2013.

[48] I. Semova, J. D. Carter, J. Stombaugh et al., "Microbiota regulate intestinal absorption and metabolism of fatty acids in the zebrafish," *Cell Host & Microbe*, vol. 12, no. 3, pp. 277–288, 2012.

[49] T. Chen, Y. You, G. Xie et al., "Strategy for an association study of the intestinal microbiome and brain metabolome across the lifespan of rats," *Analytical Chemistry*, vol. 90, no. 4, pp. 2475–2483, 2018.

[50] R. A. M. Haast and A. J. Kiliaan, "Impact of fatty acids on brain circulation, structure and function," *Prostaglandins, Leukotrienes and Essential Fatty Acids*, vol. 92, pp. 3–14, 2015.

[51] J. D. Hoffman, I. Parikh, S. J. Green et al., "Age drives distortion of brain metabolic, vascular and cognitive functions, and the gut microbiome," *Frontiers in Aging Neuroscience*, vol. 9, p. 298, 2017.

[52] S. Westfall, N. Lomis, I. Kahouli, S. Y. Dia, S. P. Singh, and S. Prakash, "Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis," *Cellular and Molecular Life Sciences*, vol. 74, no. 20, pp. 3769–3787, 2017.

[53] R. Lin, W. Liu, M. Piao, and H. Zhu, "A review of the relationship between the gut microbiota and amino acid metabolism," *Amino Acids*, vol. 49, no. 12, pp. 2083–2090, 2017.

[54] J. W. Griffin and P. C. Bradshaw, "Amino acid catabolism in Alzheimer’s disease brain: friend or foe?", *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 5472792, 15 pages, 2017.

[55] J. N. van der Veen, J. P. Kennelly, S. Wan, J. E. Vance, D. E. Vance, and R. L. Jacobs, "The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease," *Biochimica et Biophysica Acta (BBA) - Biomembranes*, vol. 1839, no. 9, pp. 1558–1572, 2017.

[56] E. Califzada, O. Onagka, and S. M. Claypool, "Phosphatidylethanolamine metabolism in health and disease," *International Review of Cell and Molecular Biology*, vol. 321, pp. 29–88, 2016.

[57] W. H. W. Tang and S. L. Hazen, "The contributory role of gut microbiota in cardiovascular disease," *Journal of Clinical Investigation*, vol. 124, no. 10, pp. 4204–4211, 2014.

[58] T. C. Fung, C. A. Olson, and E. Y. Hsiao, "Interactions between the microbiota, immune and nervous systems in health and disease," *Nature Neuroscience*, vol. 20, no. 2, pp. 145–155, 2017.

[59] T. G. Dinan and J. F. Cryan, "Microbes, immunity, and behavior: psychoneuroimmunology meets the microbiome," *Neuropsychopharmacology*, vol. 42, no. 1, pp. 178–192, 2017.

[60] C. T. Skennerton, M. F. Haroon, A. Briegel et al., "Phylogenomic analysis of Candidatus "Izimaplasma" species: free-living representatives from a Tenericutes clade found in methane seeps," *The ISME Journal*, vol. 10, no. 11, pp. 2679–2692, 2016.

[61] L. Lindmehl, M. Bashir, J. Munzker et al., "Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): a pilot study," *PLoS One*, vol. 12, no. 1, Article ID e0168390, 2017.

[62] J. S. Metcalf and G. A. Codd, "Cyanobacteria, neurotoxins and water resources: are there implications for human neurodegenerative disease?", *Amyotrophic Lateral Sclerosis*, vol. 10, no. 2, pp. 74–78, 2009.

[63] F. D. Mello, N. Braidy, H. Marçal, G. Guillemin, S. M. Nabavi, and B. A. Neilan, "Mechanisms and effects posed by neurotoxic products of cyanobacteria/microbial eukaryotes/di-noflagellates in algae blooms: a review," *Neurotoxicology Research*, vol. 33, no. 1, pp. 153–167, 2018.

[64] I. Iatsenko, J.-P. Boquete, and B. Lemaitre, "Microbiota-derived lactate activates production of reactive oxygen species by the intestinal NADPH oxidase nox and shortens drosophila lifespan," *Immunity*, vol. 49, no. 5, pp. 929–942.e8, 2018.

[65] L. K. Ursell, H. J. Haiser, W. van Treuren et al., "The intestinal metabolome: an intersection between microbiota and host," *Gastroenterology*, vol. 146, no. 6, pp. 1470–1476, 2014.

[66] C. Jiang, G. Li, P. Huang, Z. Liu, and B. Zhao, "The gut microbiota and Alzheimer’s disease," *Journal of Alzheimer’s Disease*, vol. 58, no. 1, pp. 1–15, 2017.

[67] V. M. Junges, V. E. Closs, G. M. Nogueira, and M. G. V. Gottlieb, "Crosstalk between gut microbiota and central nervous system: a focus on Alzheimer’s disease," *Current Alzheimer Research*, vol. 15, no. 13, pp. 1179–1190, 2018.

[68] L. J. Spielman, D. L. Gibson, and A. Klegeris, "Unhealthy gut, unhealthy brain: the role of the intestinal microbiota in..."
neurodegenerative diseases,” *Neurochemistry International*, vol. 120, pp. 149–163, 2018.

[69] X. Hu, T. Wang, and F. Jin, “Alzheimer’s disease and gut microbiota,” *Science China Life Sciences*, vol. 59, no. 10, pp. 1006–1023, 2016.

[70] M. Mapstone, F. Lin, M. A. Nalls et al., “What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer’s disease,” *Neurobiology of Aging*, vol. 51, pp. 148–155, 2017.

[71] J. M. Wilkins and E. Trushina, “Application of metabolomics in Alzheimer’s disease,” *Frontiers in neurology*, vol. 8, p. 719, 2017.

[72] R. González-Domínguez, A. Sayago, and Á. Fernández-Recamales, “Metabolomics in Alzheimer’s disease: the need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology,” *Journal of Chromatography B*, vol. 1071, pp. 75–92, 2017.

[73] X. Pan, M. B. Nasaruddin, C. T. Elliott et al., “Alzheimer’s disease-like pathology has transient effects on the brain and blood metabolome,” *Neurobiology of Aging*, vol. 38, pp. 151–163, 2016.